Ascensia partnership puts the London healthtech’s microsensor on the road to a European launch – with ambitions that run well beyond glucose. There is a neat irony in a fingerstick company funding the device that might make fingersticks unnecessary. Ascensia Diabetes Care, maker of the CONTOUR blood glucose meters, has led a $36 million Series B in Sava Technologies, the London healthtech whose microsensor reads glucose from just beneath the skin. It has also agreed to commercialize and distribute the device in Europe once it is approved – which suggests Ascensia sees more future in the sensor than in defending the meter. Sava has now raised $68 million in total, and this round goes on the less photogenic end of medtech: production lines, commercial readiness and a pivotal clinical study. CE approval and a European launch are penciled in for 18 to 24 months from now. Glucose is the first molecule on Sava’s list. It was never meant to be the last. Longevity.Technology: Sava’s latest funding round is significant, but arguably more interesting is its partnership with Ascensia – a sign that the company is moving beyond proving its tech works to tackling the rather less glamorous, but equally important,…

MUST’s RETRO-EPIGERNA team won $1 million and

A new partnership is combining a blood test, a c

Neither the FDA nor EMA recognizes aging as an i

Oxford biotech secures $47 million to scale cell

The MINIGRAPH consortium, funded by the European

Avaí Bio and Austrianova held a first joint stee

Restore Hyper Wellness and Niagen Bioscience have

Life Biosciences released interim Phase 1 data fr

Deep Longevity’s new US telehealth platform, A

The Parkinson’s enzyme therapy is still headin

The Austin-based microbiome testing company raise

Swedish biotech will present the Phase II ADVANC

Cognition Therapeutics will meet the agency on 2

European Parliament conference calls for coordin

Jupiter Neurosciences has dosed the first patient

Cerevance announced positive topline results from

AgelessRx has launched GHK-Cu Cream, a prescripti

First-in-human ER-100 data support dose escalati

HepaRegeniX’s darizmetinib clears milestone in

Novartis’ President of Biomedical Research, Fi

Promis Neurosciences appointed Ivana Rubino, Ph.

Shift published research in Nature Biotechnology

Maze Therapeutics will present data for its lead

A peer-reviewed preclinical study published in Ex

Bexorg was awarded up to $28.

Researchers say women in Bolotana are reaching 1

As health data multiplies, Longevitix is buildin

At LIC 2026, investors, scientists and founders

Designerly’s Cooper Adwin looks at why generat

The company says its four-year lifespan screen f

New Singapore masterclass will give senior leade

A five-year NIA grant puts UCLA Health in charge

Chinese biotechs can run trials 50–70% faster

San Mateo-based Cala has launched nationwide avai

Resolution Therapeutics announced that interim da

Circular Genomics and Altoida are combining a bl

Mito now offers a coronary artery calcium scan w

The Miami longevity startup says it hopes to rea

AbbVie’s JUVMO (tavapadon) targets dopamine di

Six of ten patients in a small trial improved by

Alector has granted Genentech exclusive worldwide

Coya Therapeutics has completed enrollment of the

Alterity presented additional analyses of its ATH

Genflow Biosciences presented interim results fro

Deerfield’s Jim Flynn on shrinking error bars,

Annovis Bio is using an AI tool to speed up its

Aged beagle data hint at lower biological age an

ARDD moved from Copenhagen to Boston out of nece

As peptides surge in popularity, better evidence